Clinically Significant Lower Elvitegravir Exposure During The Third Trimester Of Pregnant Patients Living With Human Immunodeficiency Virus: Data From The Pharmacokinetics Of Antiretroviral Agents In Hiv-Infected Pregnant Women (Panna) Network

This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (C-trough) was reduced by 77%, with 85% of pregnant women having a C(trough )below the effective concentration (EC90).